Septerna Inc. has reported its financial results for the second quarter of 2025. The company experienced a net loss of $24.8 million for the quarter ended June 30, 2025, compared to a net loss of $16.4 million in the same period the previous year. Research and development expenses rose to $22.2 million from $15.0 million year-over-year, reflecting an increase in R&D activities. General and administrative expenses also increased to $6.9 million from $3.4 million in the previous year. In terms of cash position, Septerna's cash, cash equivalents, and marketable securities stood at $379.2 million as of June 30, 2025. Following the receipt of a $195 million upfront payment from Novo Nordisk in July, the company now expects its cash runway to extend at least into 2029. Significant business updates include advancing the selection of a next-generation oral small molecule PTH1R agonist for clinical development and initiating a Phase 1 trial for SEP-631, MRGPRX2 NAM program, targeting mast cell diseases. Septerna continues to pioneer in the field of G protein-coupled receptor $(GPCR)$ drug discovery.